Jubilant Ingrevia Q4 Revenue Rises 12 Per Cent
ECONOMY & POLICY

Jubilant Ingrevia Q4 Revenue Rises 12 Per Cent

Jubilant Ingrevia reported a healthy performance in Q4 FY26, with revenue rising 12 per cent year-on-year and EBITDA increasing 11 per cent year-on-year. The company said strong execution, resilient demand and effective handling of Middle East disruptions supported its quarterly performance.

The company highlighted that it faced no force majeure and recorded zero production loss during the Middle East crisis. It also achieved successful dispatch from its newly constructed Agro CDMO facility and completed the acquisition of Remidex to accelerate growth in its Human Nutrition business.

The Board recommended a final dividend of Rs 2.50 per share, taking the total FY26 dividend to Rs 5 per share. The company said demand across the chemical industry remains resilient, with volumes growing and pricing firming up due to higher crude-linked costs.

Pharmaceuticals continued to support growth through strong volumes and steady demand, while the agrochemicals business saw strong export visibility and price increases. Nutrition and Personal Care markets also grew, driven by Niacinamide and demand across Feed and Cosmetics.

For FY27, Jubilant Ingrevia expects growth to be led by Specialty Chemicals and Nutrition, supported by recovery in Acetyls. The company also said construction of its Gajraula Multi Purpose Plant is progressing well and will strengthen its CDMO growth roadmap.

Jubilant Ingrevia reported a healthy performance in Q4 FY26, with revenue rising 12 per cent year-on-year and EBITDA increasing 11 per cent year-on-year. The company said strong execution, resilient demand and effective handling of Middle East disruptions supported its quarterly performance.The company highlighted that it faced no force majeure and recorded zero production loss during the Middle East crisis. It also achieved successful dispatch from its newly constructed Agro CDMO facility and completed the acquisition of Remidex to accelerate growth in its Human Nutrition business.The Board recommended a final dividend of Rs 2.50 per share, taking the total FY26 dividend to Rs 5 per share. The company said demand across the chemical industry remains resilient, with volumes growing and pricing firming up due to higher crude-linked costs.Pharmaceuticals continued to support growth through strong volumes and steady demand, while the agrochemicals business saw strong export visibility and price increases. Nutrition and Personal Care markets also grew, driven by Niacinamide and demand across Feed and Cosmetics.For FY27, Jubilant Ingrevia expects growth to be led by Specialty Chemicals and Nutrition, supported by recovery in Acetyls. The company also said construction of its Gajraula Multi Purpose Plant is progressing well and will strengthen its CDMO growth roadmap.

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code